M&A/corporate and commercial
Michael Cohen of Brown Rudnick LLP is a seasoned attorney specializing in life sciences, venture capital, and emerging companies. With expertise in cross-border transactions, Cohen advises both investors and startups on financing and M&A. Notable matters include leading $175m in Series B financing for Aktis Oncology and assisting MPM BioImpact in a $40m Series A investment for āshibio.
Legal 500 Editorial commentary
Accolades
Boston Elite
Mentions
Profile
Work Department
Life Sciences Group, Emerging Growth Companies and Venture Capital Group
Position
Partner
Career
Michael Cohen is co-practice group leader of Brown Rudnick’s Global Life Sciences Group and of the firm’s Emerging Growth Companies & Venture Capital Group. He advises on high-profile matters in the life sciences and technology sectors. Michael's clients regularly rely on him to be a true outside general counsel, ready and able to handle matters big and small as they arise.
Michael represents early stage and mid-market companies in corporate structuring, mergers and acquisitions, joint ventures and strategic alliances, financing transactions, and other general transactional matters at all stages of the corporate life cycle. Michael also advises venture, hedge, and private equity funds, universities, corporate venture groups, and portfolio companies in connection with financing transaction deal terms and stockholders' agreements, technology licensing, corporate governance and securities law compliance in connection with private offerings.
Michael also works closely with Brown Rudnick’s London office in counseling U.K. and European clients engaging in transactions involving U.S. concerns.
Content supplied by Brown Rudnick LLP
Key clients
- Aktis Oncology, a biotechnology company.
- Crossbow Therapeutics, a biotechnology company.
- MPM BioImpact, a biotechnology investment firm.
Work highlights
- Represented Aktis Oncology in its oversubscribed $175m Series B financing, led by RA Capital, RTW Investments, and Janus Henderson Investors, continuing its support for the biotech company developing targeted radiopharmaceuticals for solid tumor cancers.
- Led MPM BioImpact in its $40m investment in California-based biotech company āshibio’s Series A funding round, supporting the development of novel therapies, including a potential treatment for fibrodysplasia ossificans progressiva (FOP).
- Represented Crossbow Therapeutics in its $80m Series A financing, led by MPM BioImpact and Pfizer Ventures, to advance the development of novel cancer therapies targeting peptide-loaded major histocompatibility complexes (pMHCs) on cancer cells.